Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | ALOX5AP | P20292 | 1/20 | 1.00 |
| ▸ | EPOR | P19235 | 8/20 | 0.68 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | TLR4 | O00206 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808733 | 1.00 | ALOX5 (1.00) | ALOX5PTGS1PTGS2ALOX5APEPOR | |
| SCHEMBL3899072 | 1.00 | ALOX5 (1.00) | ALOX5PTGS1PTGS2ALOX5APEPOR | |
| SCHEMBL9707330 | 0.82 | ALOX5 (0.69) | ALOX5PTGS1PTGS2ALOX5APEPOR | |
| SCHEMBL26357305 | 0.80 | ALOX5 (0.67) | ALOX5PTGS1PTGS2ALOX5APEPOR | |
| SCHEMBL9707266 | 0.76 | ALOX5 (0.61) | ALOX5PTGS1PTGS2ALOX5APEPOR | |
| SCHEMBL9781059 | 0.76 | ALOX5 (0.70) | ALOX5PTGS1PTGS2ALOX5APEPOR | |
| SCHEMBL9781055 | 0.76 | ALOX5 (0.70) | ALOX5PTGS1PTGS2ALOX5APEPOR | |
| SCHEMBL6008832 | 0.75 | ALOX5 (0.66) | ALOX5PTGS1PTGS2ALOX5APEPOR | |
| SCHEMBL6008836 | 0.75 | ALOX5 (0.66) | ALOX5PTGS1PTGS2ALOX5APEPOR | |
| SCHEMBL6008840 | 0.75 | ALOX5 (0.66) | ALOX5PTGS1PTGS2ALOX5APEPOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6183960-A | — | — | None | — | — | JP | disclosed |
| US-11773111-B1 | Selective 5-LO inhibitors for the treatment of bronchial asthma | King Faisal University (SA) | 2023-10-03 | — | — | US | disclosed |
| US-11773111-B1 | Selective 5-LO inhibitors for the treatment of bronchial asthma | King Faisal University (SA) | 2023-10-03 | — | — | US | disclosed |
| US-11724991-B1 | Selective 5-LO inhibitors for the treatment of bronchial asthma | King Faisal University (SA) | 2023-08-15 | — | — | US | disclosed |
| US-11724991-B1 | Selective 5-LO inhibitors for the treatment of bronchial asthma | King Faisal University (SA) | 2023-08-15 | — | — | US | disclosed |
| EP-3341366-A1 | TOCOTRIENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN 5-LIPOXYGENASE RELATED DISEASES | Université d'Angers (FR) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017032881-A1 | TOCOTRIENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN 5-LIPOXYGENASE RELATED DISEASES | Université d'Angers (FR) | 2017-03-02 | — | — | WO | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20140171445-A1 | TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-06-19 | — | — | US | disclosed |
| EP-1572185-A4 | LIPOXYGENASE INHIBITORS AS HYPOLIPIDEMIC AND ANTI-HYPERTENSIVE AGENTS | INSMED INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-1572185-A1 | LIPOXYGENASE INHIBITORS AS HYPOLIPIDEMIC AND ANTI-HYPERTENSIVE AGENTS | Insmed Incorporated (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040198800-A1 | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents | INSMED INCORPORATED | 2004-10-07 | — | — | US | disclosed |
| WO-2004058240-A1 | LIPOXYGENASE INHIBITORS AS HYPOLIPIDEMIC AND ANTI-HYPERTENSIVE AGENTS | INSMED INCORPORATED (US) | 2004-07-15 | — | — | WO | disclosed |
| JP-H06183960-A | SUPPRESSOR FOR VASCULAR WALL HYPERPLASIA | TERUMO CORP | 1994-07-05 | — | — | JP | disclosed |
| EP-0299761-B1 | ANTI-INFLAMMATORY ARYL DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-18 | — | — | EP | disclosed |
| US-4988733-A | Also used in treatment of cardiovascular disorders and inflammation | BURROUGHS WELLCOME CO. (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0299761-A1 | Anti-inflammatory aryl derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773111-B1 | Selective 5-LO inhibitors for the treatment of bronchial asthma | ALOX5, LTC4S, NOX5 | ALOX5 1/4885PTGS1 150/4885PTGS2 94/4885 |
| US-20040198800-A1 | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents | ALOX5, ALOX15, ALOX15B | ALOX5 1/4885PTGS1 14/4885PTGS2 13/4885 |
| US-11724991-B1 | Selective 5-LO inhibitors for the treatment of bronchial asthma | ALOX5, LTC4S, NOX5 | ALOX5 1/4885PTGS1 173/4885PTGS2 103/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | ALOX5 25/4885PTGS1 76/4885PTGS2 99/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | ALOX5 10/4885PTGS1 593/4885PTGS2 1253/4885 |
| US-20140171445-A1 | TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE | ALOX5, ALOX15, ALOX15B | ALOX5 1/4885PTGS1 19/4885PTGS2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.